Tempus AI (TEM) spent three years selling someone else’s cancer test. On Monday, July 20, it decided to just buy the whole thing.
The AI diagnostics company agreed to acquire Personalis (PSNL) in a deal valued at $1.5 billion.
The move hands Tempus full control of a test that spots cancer coming back before a scan ever could.
Investors did not treat it as a win. Tempus stock dropped, and it has kept sliding since.
That gap between the strategy and the stock price is worth understanding. Wall Street likes the deal. It just does not want to pay for it yet.
What Tempus is buying with the Personalis deal
According to a Tempus press release, the company is paying $16.25 per share for Personalis, valuing the company at $1.5 billion, including debt.
That works out to a 6% increase over the prior Friday, July 17, close and a 28% jump against the 30-day average price.
More Tech Stocks:
- Cathie Wood buys $36.1 million of tumbling tech stock
- Citi revamps Microsoft stock price target for the rest of 2026
- Top-rated analyst sets a jaw-dropping Intel stock price target
The prize is a test called NeXT Personal. It tracks tiny fragments of tumor DNA in the blood to catch what doctors call minimal residual disease, or MRD.
MRD is the cancer that lingers after surgery or chemo and hides below the reach of normal scans.
The two companies have worked together previously. Tempus invested in Personalis back in November 2023 and has sold the test through its own sales force ever since, according to Reuters.
This deal turns that partnership into ownership.
Why owning the whole cancer test matters more than sharing it
Under the old setup, Tempus split the money from every NeXT Personal test it sold. Full ownership means every dollar now flows to one place.
That matters because the market is large. Tempus and Personalis peg the MRD opportunity at roughly $20 billion, and fewer than 10% of eligible patients are tested today, according to MedCity News.
The test is also selling fast. Personalis reported preliminary second-quarter revenue of $22.4 million.
The company also ran 10,384 clinical tests, which is a 33% jump in volume from the prior quarter, Quartz reported.
The data engine behind the deal
There is a second reason for Tempus to own Personalis outright.
Tempus sits on a library of more than 8 million de-identified patient records, and it rents access to that data to drugmakers. The company’s SEC filing showed that Insights, which is Tempus’ data-licensing arm, grew about 44% in the first quarter.
Folding Personalis genomic data into that library makes the whole thing more valuable to drugmaker partners. AstraZeneca (AZN), for instance, is paying Tempus up to $200 million across a multi-year model-building deal, Fierce Biotech noted.
GSK is another. More data means more leverage in those contracts.
In plain terms, Tempus is not just buying a test. It is also buying more of the raw material its most profitable business runs on.
Why Tempus stock fell, even though the logic holds
If the strategy is sound, why did the stock drop close to 9% on the day and keep falling to about $49 by Tuesday, July 21?
The answer comes down to how the deal gets paid for.
This is mostly a stock transaction, which means Tempus will issue new shares to Personalis holders.
Related: UnitedHealth CFO sends stark warning after earnings
New shares dilute existing owners, and markets tend to punish that first and ask questions later, according to TipRanks.
Tempus can also pay up to half in cash. If it does, that cash comes from its balance sheet and credit lines, and the company already carries a debt-to-equity ratio of around 2.45.
The timing problem investors are stuck on
There is also a timing concern. The deal is not expected to close until late 2026 or early 2027, pending a Personalis shareholder vote and regulatory sign-off.
That means investors absorb the dilution risk now and wait more than a year for the benefits, Benzinga reported.
Tempus was already tracking toward adjusted EBITDA of about $65 million for 2026, a milestone that signals the business is nearing self-sustaining cash generation.
Absorbing Personalis costs could delay that milestone.
What Wall Street analysts still see in Tempus
Here is the part that complicates the sell-off. The analysts who cover Tempus mostly ignored the drop.
Morgan Stanley called the case compelling and pointed out that about 80%of Personalis clinical volume already runs through Tempus channels, according to Stocktwits.
That limits the integration mess that usually affects acquisitions.
Needham kept its buy rating and a $75 target, according to Investing.com.
The average price target across 15 analysts sits at $65.77, well above where the stock trades now.
The bull case, in plain terms
For the outlook to work from here, a few things need to line up.
- The deal closes on schedule without regulators forcing changes.
- MRD testing keeps growing volume the way it did last quarter.
- The data-licensing business keeps signing pharma deals.
- Tempus holds its path toward positive adjusted EBITDA, despite the added costs.
None of those are guaranteed. The stock trades below its 52-week high of $104.32 for a reason, and a company still posting losses has less room for a misstep.
How Tempus stock stacks up right now
Tempus shares have had a rough stretch. The stock is down about 16% over the past five trading days and roughly 21% from the start of the year. It is now trading near $49.39.
That is a long way from the highs, but it also sits above the 52-week low of $41.73.
The next real test is approaching soon.
Tempus reports earnings on July 30, and management will field direct questions about how it plans to pay for Personalis without stalling its own profitability, Benzinga noted.
What this means for investors watching Tempus
The Personalis deal gives Tempus something rare: a leading position in a market that is barely tapped, and a richer data set to sell to the world’s biggest drugmakers, Bloomberg reported.
The payoff will not show up soon. Investors have to accept dilution and a heavier debt load now, in hopes of a market that pays off in 2027 and beyond.
Long-term holders who buy the AI-and-oncology outlook may see the drop as noise around a sound strategy.
Anyone focused on the next few quarters should watch the earnings call on July 30. It will say more than the deal announcement did.
Either way, watch the gap between what Tempus is building and what its stock is doing. That gap is the clearest signal on the table right now.
Related: Stanford Health AI Week: How AI Can Support Aging in Place
